HAIFA, Israel, August 17 /PRNewswire/ -- InSightec, Ltd. has signed a
worldwide sales and marketing agreement with GE Healthcare, a unit of General
Electric Company (NYSE: GE), for the sales and marketing of its ExAblate(R)
2000, a Magnetic Resonance guided Focused Ultrasound surgery (MRgFUS) system,
the company said today. ExAblate 2000 is a non-invasive therapy system that
combines magnetic resonance imaging (MRI) with highly focused ultrasound to
thermally ablate (destroy) tumors in the body. The ExAblate 2000 works
exclusively with the Signa MR systems made by GE Healthcare.
Under the terms of this agreement, GE Healthcare will have exclusive
worldwide distribution rights for ExAblate except in Japan and Russia where
InSightec already has existing distributors and representatives. InSightec
and GE Healthcare will also collaborate on marketing and research and
development. The agreement is for five years, effective immediately. GE is a
minority shareholder in InSightec.
"We are very pleased to have a formal agreement with GE Healthcare, the
leader in the MR marketplace," Dr. Jacob Vortman, president and CEO,
InSightec, said. "This relationship offers a clear differentiation for GE
Healthcare, while allowing us to accelerate penetration of our MR guided
Focused Ultrasound technology in markets around the world."
The ExAblate 2000 is the first U.S. Food and Drug Administration (FDA)
approved system to use the breakthrough MRgFUS technology that combines MRI
-- to visualize tissues in the body, plan the treatment and monitor in real
time treatment outcome -- and high intensity focused ultrasound to thermally
ablate tissue. MR thermal feedback, provided uniquely by the system, allows
the physician to control and adjust the treatment in real time to ensure that
the targeted tumor is fully treated and surrounding tissue is spared. To date
approximately 1200 women have been treated with ExAblate 2000 for uterine
fibroids, a benign condition that affects approximately 25% of women, and
clinical trials are underway for bone, liver, and breast tumors.
InSightec Image Guided Treatment Ltd. is a privately held company owned
by Elbit Medical Imaging (EMI), General Electric, private investors and
employees. It was founded in 1999 to develop the breakthrough MR guided
Focused Ultrasound technology and transform it into the next generation
operating rooms. Headquartered near Haifa, Israel, the company has over 100
employees and has invested more than $80 million in research, development,
and clinical investigations. Its U.S. headquarters are located in Dallas,
Texas. For more information, please go to: http://www.insightec.com/
About GE Healthcare
GE Healthcare provides transformational medical technologies that are
shaping a new age of patient care. GE Healthcare's expertise in medical
imaging and information technologies, medical diagnostics, patient monitoring
and life support systems, disease research, drug discovery, and
biopharmaceutical manufacturing technologies is helping physicians detect
disease earlier and tailor personalized treatments for their patients. GE
Healthcare offers a broad range of products and services that are improving
productivity in healthcare and enhancing patient care by enabling healthcare
providers to better diagnose and treat cancer, heart disease, neurological
diseases, and other conditions.
GE Healthcare is a $15 billion unit of General Electric Company (NYSE:
GE) headquartered in the United Kingdom. Worldwide, GE Healthcare employs
more than 43,000 people committed to serving healthcare professionals and
their patients in more than 100 countries. For more information about GE
Healthcare, visit our website at www.gehealthcare.com.
For media inquiries, contact:
Lazar Partners, Ltd.
SOURCE Insightec Ltd.